Journal Article Research Support, Non-U.S. Gov't Ppublish 22 citations
PubMed: 38323780 DOI: 10.1002/alz.13687
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.
Alzheimers Dement 20(4):2453-2468
Authors: Giovanni Bellomo, Sherif Bayoumy, Alfredo Megaro, Andrea Toja, Giovanna Nardi, Lorenzo Gaetani, Elena R Blujdea, Federico Paolini Paoletti, Anna Lidia Wojdaƚa, Davide Chiasserini, Wiesje M van der Flier, Inge M W Verberk, Charlotte Teunissen, Lucilla Parnetti
Affiliations
- Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
- Section of Biochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Abstract
INTRODUCTION
For routine clinical implementation of Alzheimer's disease (AD) plasma biomarkers, fully automated random-access platforms are crucial to ensure reproducible measurements. We aimed to perform an analytical validation and to establish cutoffs for AD plasma biomarkers measured with Lumipulse.
METHODS
Two cohorts were included. UNIPG: n = 450 paired cerebrospinal fluid (CSF)/plasma samples from subjects along the AD-continuum, subjects affected by other neurodegenerative diseases, and controls with known CSF profile; AMS: n = 40 plasma samples from AD and n = 40 controls. Plasma amyloid β (Aβ)42, Aβ40, and p-tau181 were measured with Lumipulse. We evaluated analytical and diagnostic performance.
RESULTS
Lumipulse assays showed high analytical performance. Plasma p-tau181 levels accurately reflected CSF A+/T+ profile in AD-dementia and mild cognitive impairment (MCI)-AD, but not in asymptomatic-AD. Plasma and CSF Aβ42/40 values were concordant across clinical AD stages. Cutoffs and probability-based models performed satisfactorily in both cohorts.
DISCUSSION
The identified cutoffs and probability-based models represent a significant step toward plasma AD molecular diagnosis.
MeSH
Research Design, Dementia, Alzheimer Disease, Probability, Cognitive Dysfunction, Biomarkers, Plasma
Cited by
- Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy. NPJ Parkinsons Dis, 2025
- Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease and Other Dementias: A Center-Based Study. Int J Mol Sci, 2025
- Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse platform. Fluids Barriers CNS, 2025
- Plasma p-tau217 and p-tau217/Aβ1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer's disease: Insights for research and clinical practice. Alzheimers Dement, 2025
- Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study. J Prev Alzheimers Dis, 2025
- A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease. EBioMedicine, 2025
- Blood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer's disease and behavioral-variant frontotemporal dementia. Alzheimers Res Ther, 2024
- Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain, 2025